We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

INGA:EURONEXT AMSTERDAMING Groep N.V. Analysis

Data as of 2026-06-24 - not real-time

€27.81

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

ING shares are trading at €27.81, comfortably above the 20‑day SMA (≈26.6) and the 50‑day SMA (≈25.7), confirming a bullish trend. The 200‑day SMA sits near €23.7, providing a long‑term support cushion. Momentum indicators are strong, with RSI at 65 and a bullish MACD crossover (histogram positive). Volatility over the past 30 days is about 24%, but the stock’s beta of 0.58 indicates lower systematic risk than the market. The forward PE of 9.8 versus a trailing PE of 12.7 suggests earnings are expected to improve. Relative to the industry average PE of 17, the stock appears undervalued.
The company’s dividend yield of 3.9% and a payout ratio under 50% underline dividend sustainability. Recent execution of the €1 billion share‑buyback programme, with 1.5 million shares repurchased this week, signals confidence from management. Earnings per share are projected to rise from €2.19 to €2.83, reflecting modest profit growth. The balance sheet shows ample cash relative to debt, and the low leverage reduces financial risk. The “Extreme Greed” sentiment in the fear‑greed index aligns with the bullish technical setup. Overall, the combination of attractive valuation, solid fundamentals, and supportive corporate actions justifies a buy recommendation.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • Bullish momentum (RSI 65, MACD bullish)
  • Price above 20‑day and 50‑day SMAs with strong support
  • Recent share‑buyback execution reinforcing price

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued relative to industry PE
  • Attractive dividend yield and sustainable payout
  • Stable earnings growth and modest upside potential

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong balance sheet with high cash reserves
  • Low beta indicating defensive profile
  • Consistent dividend policy and ongoing capital return programs

Key Metrics & Analysis

Financial Health

Revenue Growth2.90%
Profit Margin34.23%
P/E Ratio12.7
ROE16.57%
ROA0.78%
P/B Ratio1.6
Industry P/E17.0

Technical Analysis

TrendBullish
RSI65.4
Support€24.82
Resistance€28.17
MA 20€26.58
MA 50€25.71
MA 200€23.68
MACDBullish
VolumeStable
Fear & Greed Index87.32

Valuation

Target Price€28.31
Upside/Downside1.80%
GradeUndervalued
TypeBlend
Dividend Yield3.89%

Risk Assessment

Beta0.58
Volatility23.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.